StockData
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. (FDMT) stock

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.46−0.33 (-3.06%)

Close on Nov 18, 2026Market cap $755.00MP/E –Yield –

4D Molecular Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

4D Molecular Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$109.62M. For fiscal 2025 it was -$109.62M. The highest annual figure on record is -$39.91M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$109.62M–
FY2024Dec 31, 2024-$138.37M–
FY2023Dec 31, 2023-$78.56M–
FY2022Dec 31, 2022-$98.22M–
FY2021Dec 31, 2021-$78.24M–
FY2020Dec 31, 2020-$51.91M–
FY2019Dec 31, 2019-$39.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$28.62M–
Q3 FY2025Sep 30, 2025-$46.41M–
Q2 FY2025Jun 30, 2025-$43.44M–
Q1 FY2025Mar 31, 2025-$48.39M–
Q4 FY2024Dec 31, 2024-$46.81M–
Q3 FY2024Sep 30, 2024-$31.17M–
Q2 FY2024Jun 30, 2024-$30.59M–
Q1 FY2024Mar 31, 2024-$29.80M–
Q4 FY2023Dec 31, 2023-$25.20M–
Q3 FY2023Sep 30, 2023-$1.58M–
Q2 FY2023Jun 30, 2023-$22.87M–
Q1 FY2023Mar 31, 2023-$28.92M–
Q4 FY2022Dec 31, 2022-$23.31M–
Q3 FY2022Sep 30, 2022-$22.98M–
Q2 FY2022Jun 30, 2022-$21.97M–
Q1 FY2022Mar 31, 2022-$29.96M–
Q4 FY2021Dec 31, 2021-$26.93M–
Q3 FY2021Sep 30, 2021-$18.36M–
Q2 FY2021Jun 30, 2021-$16.94M–
Q1 FY2021Mar 31, 2021-$16.01M–
Q4 FY2020Dec 31, 2020-$18.01M–
Q3 FY2020Sep 30, 2020-$13.02M–
Q2 FY2020Jun 30, 2020-$6.29M–
Q1 FY2020Mar 31, 2020-$14.59M–

More 4D Molecular Therapeutics figures

See a number that looks wrong?